세계의 CRISPR와 Cas 유전자 시장 규모 : 유형별, 용도별, 최종사용자별, 지역 범위별 및 예측

CRISPR And Cas Genes Market Size And Forecast

CRISPR And Cas Genes Market size was valued at USD 2903.05 Million in 2024 and is projected to reach USD 8861.98 Million by 2032, growing at a CAGR of 14.97% from 2026 to 2032.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas (CRISPR-associated) genes are revolutionary genetic editing tools. CRISPR is a natural defense mechanism in bacteria that identifies and cuts foreign DNA, while Cas proteins, such as Cas9, operate as molecular scissors to perform these cuts. This technique has been developed for application in a wide range of organisms, allowing for precise genetic sequence modifications. Gene therapy to rectify genetic problems, agricultural biotechnology to improve crop resistance and productivity, and the creation of novel treatments by targeting disease-associated genes are among the various uses.

The CRISPR and Cas genes are extensive and promising. Advances in this technique are likely to lead to breakthroughs in personalized medicine, with genetic medicines customized to individual genetic profiles for maximum efficacy. Innovations in CRISPR precision and delivery mechanisms are likely to expand its use in the treatment of complicated diseases such as cancer and rare genetic abnormalities.

Furthermore, CRISPR technology is expected to propel advances in synthetic biology, allowing the production of modified creatures with unique functions. Ethical issues and legal frameworks will be critical in directing these advancements and guaranteeing their responsible implementation.

Global CRISPR And Cas Genes Market Dynamics

The key market dynamics that are shaping the global CRISPR And Cas Genes Market include:

Key Market Drivers:

Increasing Prevalence of Genetic Disorders: The increasing prevalence of genetic abnormalities is a primary driver of the CRISPR And Cas Genes Market. The World Health Organization (WHO) reports that roughly 10,000 human disorders are monogenic. According to the Global Genes Project, 300 million people worldwide suffer from rare diseases, the majority of which are hereditary. This large patient population generates a high demand for gene-editing technologies such as CRISPR for possible treatments.

Rising Investments in Genomics Research: The CRISPR And Cas Genes Market forward by speeding advances in gene-editing technologies. From 2016 to 2020, the US government financed more than $3.8 billion on genomics research, with the UK's Medical Research Council committing £200 million in 2022. This enormous funding promotes innovation, large-scale studies, and the development of CRISPR-based medicines, making it an essential factor in market growth.

Expanding Applications in Agriculture and Food Production: CRISPR technology is driving breakthroughs in agriculture by boosting crop yields and developing robust plant varieties to fulfill rising global food demand. With the Food and Agriculture Organization (FAO) anticipating a 60% increase in agricultural productivity by 2050, CRISPR is being extensively embraced, as indicated by a 2019 article in Nature Plants, which found CRISPR-edited crops grown in over 20 nations. This growing application of CRISPR in agriculture promotes food security and sustainability, making it an important driver in the market.

Key Challenges:

Ethical Concerns: The use of CRISPR technology presents significant ethical concerns, notably about germline editing and its unintended consequences. Editing human embryos or making alterations that may be inherited by future generations raises concerns about the implications over time for human genetics. These ethical considerations can cause regulatory delays and influence public perception, reducing acceptance and investment in CRISPR-based solutions.

Cost of Research and Development: Developing and commercializing CRISPR-based technologies incurs enormous R&D costs. The high costs associated with innovation, regulatory compliance, and clinical trials can make it difficult for smaller enterprises and research institutes to compete in the market. This costly hurdle hinders progress and reduces the availability of CRISPR-based therapies.

Biosecurity Risks: The possible misuse of CRISPR technology raises biosecurity concerns, such as the development of risky genetic changes or bioweapons. To avoid these concerns, CRISPR technology must be utilized responsibly and with proper protections in place. Addressing biosecurity concerns is critical for the technology's credibility and safe use.

Key Trends:

Precision and Efficiency Advancements: Recent developments, including enhancements in Cas9 variations and the introduction of new CRISPR-associated systems, have considerably improved CRISPR technology's precision and efficiency. These developments lessen off-target effects while increasing editing accuracy, making CRISPR more trustworthy for therapeutic applications. The desire for more precise gene editing is fueling research and clinical trials, increasing the technology's promise for treating genetic abnormalities and other diseases.

Growth in Agricultural Biotechnology: CRISPR is being used to generate genetically modified crops with enhanced features such as increased yield, disease resistance, and stress tolerance. The technology's capacity to make precise genetic changes is pushing its use in agricultural research. This trend promotes sustainable farming techniques and improves food security, generating major interest and investment in the agriculture sector.

Advancement in Ethical and Regulatory Frameworks: Clearer ethical principles and regulatory frameworks are making it easier to employ CRISPR technology responsibly. As rules become more defined, researchers and businesses acquire a greater understanding of the acceptable use of CRISPR, facilitating its integration into clinical practice and commercial products. This tendency is boosting confidence and growth in the CRISPR market.

Emergence of Novel CRISPR Systems: The discovery and development of novel CRISPR systems beyond Cas9, such as CRISPR/Cas12 and CRISPR/Cas13, is ongoing. These innovative systems have distinct traits and applications, including fewer off-target impacts and increased targeting capabilities. Exploration of these systems drives innovation and broadens the possible applications of CRISPR technology, hence supporting market growth.

Global CRISPR And Cas Genes Market Regional Analysis

Here is a more detailed regional analysis of the global CRISPR And Cas Genes Market:

North America:

North America remains a dominant player in the CRISPR And Cas Genes Market, owing to its strong research infrastructure and advanced biotechnology sector. The region's best research institutes and universities are critical to CRISPR innovation, with NIH funding increasing from USD 5.1 Million in 2011 to more than USD 603 Million in 2020, representing an unparalleled 11,725% growth. This flood of funding has resulted in a 27% annual increase in CRISPR-related publications from North American institutions, as reported by PubMed in 2022. Complementing this, North America's well-established biotechnology industry, which includes over 6,500 biotech firms in the United States, with around 12% focusing on gene editing, drives significant progress.

The region's favorable regulatory framework also helps to advance CRISPR research and commercialization. The FDA has accepted 23 Investigational New Drug (IND) applications for CRISPR-based therapies as of 2024, a 53% increase over 2020. Since 2019, the Regenerative Medicine Advanced Therapy (RMAT) designation has advanced the approval of five CRISPR-based therapeutics.

The growing number of active CRISPR-related clinical trials, which will reach 152 in North America by September 2024, a 36% increase over the previous year, illustrates CRISPR's expanding therapeutic applicability, notably in oncology. These factors contribute to North America's leadership and continuous innovation in the CRISPR And Cas Genes Market.

Asia Pacific:

The CRISPR And Cas Genes Market in Asia Pacific is expanding rapidly, owing to significant investments, increased research activity, and a big population base. Governments in the area are making considerable expenditures in biotechnology and healthcare, with biotechnology investments increasing by 32% between 2018 and 2022, according to the Asia Pacific Economic Cooperation. China has committed USD 9.2 Billion to its precision medicine project, which includes significant funding for CRISPR technology, while Japan's genome editing consumption has increased by 41% between 2019 and 2024. This funding backing has sped up the development of CRISPR-based solutions and technologies.

The Asia Pacific area has strong financial backing, vigorous research activity, and a large population, all of which fuel demand for CRISPR applications. Research institutes have dramatically boosted their contributions to CRISPR investigations, with Asia Pacific publications increasing by 28% annually between 2018 and 2022. The region's massive population, predicted to reach 4.7 billion by 2025, opens up numerous prospects for CRISPR in healthcare and agriculture. For instance, 12 Asian countries are developing CRISPR-edited crops, with field trials increasing by 45% between 2020 and 2024. The number of CRISPR-related clinical trials in Asia Pacific increased by 140% between 2019 and 2024, demonstrating the region's growing importance in worldwide CRISPR breakthroughs and applications.

Global CRISPR And Cas Genes Market: Segmentation Analysis

The Global CRISPR And Cas Genes Market is Segmented on the basis of Type, Application, End-User, And Geography.

CRISPR And Cas Genes Market, By Type

• DNA-Free Cas
• Vector-Based Cas

Based on Type, the market is bifurcated into DNA-free Cas and Vector-based Cas. The CRISPR and Cas gene market is currently dominated by vector-based Cas systems, which use viral vectors to deliver the Cas gene to cells. This method has been widely utilized due to its effectiveness and versatility. DNA-free Cas systems, which use non-viral delivery techniques, are becoming the most rapidly developing sector. These systems have advantages such as fewer off-target effects and larger safety, making them appealing for therapeutic applications. As research and development in DNA-free Cas delivery progresses, it is projected to capture considerable market share in the years ahead.

CRISPR And Cas Genes Market, By Application

• Genome Engineering
• Functional Genomics
• Disease Models

Based on Application, the market is segmented into Genome Engineering, Functional Genomics, and Disease Models. The CRISPR And Cas Genes Market is currently dominated by genome engineering applications, which include changing organisms' genetic code for a variety of reasons. This segment has grown significantly due to its ability to solve a wide range of difficulties, such as disease treatment, crop improvement, and biofuel generation. Functional genomics, which examines gene function and connections, is emerging as the most rapidly increasing segment. As researchers develop a better grasp of gene biology, functional genomics applications grow, increasing demand for CRISPR-based tools and techniques.

CRISPR And Cas Genes Market, By End-User

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Contract Research Organizations

Based on End-User, the market is segmented into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations. Biotechnology and pharmaceutical businesses now dominate the CRISPR and Cas gene market, using this technology for drug discovery, development, and therapeutic applications. These firms have significant resources and competence in translating CRISPR research into commercial goods. Academic institutions and government research institutes are emerging as the most rapidly rising area. These institutions play an important role in fundamental research, promoting innovation, and improving the area of CRISPR. Their findings are frequently used to develop commercial applications, making them important contributors to market growth.

Key Players

The "Global CRISPR And Cas Genes Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are OriGene Technologies, Inc., Thermo Fisher Scientific, Takara Bio, Inc., Horizon Discovery Ltd., Addgene, Merck KGaA, Caribou Biosciences, Inc., CRISPR therapeutics, Editas Medicine and Mirus Bio LLC. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• CRISPR And Cas Genes Market Recent Developments
• In June 2024, DNA nanobots, a biotechnology business, stated that it completed gene editing technology developed at the University of California (UC) Berkeley. The licensed intellectual property allows for the folding of genes into their own delivery devices, in conjunction with CRISPR-Cas, to provide very efficient non-viral gene delivery.
• In April 2024, Caszyme, a biotech company based in Lithuania that develops CRISPR gene-editing technology, plans to construct a new facility. The expansion seeks to help create non-complementary competencies to fulfill the growing demand for gene-editing-based systems and products across Asia, Europe, and the United States.
• In November 2022, Researchers at the Massachusetts Institute of Technology developed PASTE, a new CRISPR-based technology that inserts huge DNA sequences at targeted places in cells. The approach has the potential to treat a wide range of diseases caused by defective genes.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CRISPR AND CAS GENES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 2.1 Data mining
• 2.2 Secondary research
• 2.3 Primary research
• 2.4 Subject matter expert advice
• 2.5 Quality check
• 2.6 Final review
• 2.7 Data triangulation
• 2.8 Bottom-up approach
• 2.9 Top-down approach
• 2.10 Research flow
• 2.11 Data sources

3 EXECUTIVE SUMMARY

• 3.1 Overview
• 3.2 Absolute $ Opportunity
• 3.3 Market attractiveness
• 3.4 Future Market Opportunities

4 GLOBAL CRISPR AND CAS GENES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CRISPR AND CAS GENES MARKET, BY TYPE

• 5.1 Overview
• 5.2 DNA-free Cas
• 5.3 Vector-based Cas

6 GLOBAL CRISPR AND CAS GENES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Genome Engineering
• 6.3 Functional Genomics
• 6.4 Disease Models
• 6.5 Others

7 GLOBAL CRISPR AND CAS GENES MARKET, BY END-USER

• 7.1 Overview
• 7.2 Biotechnology & Pharmaceutical Companies
• 7.3 Academic & Government Research Institutes
• 7.4 Contract Research Organizations

8 GLOBAL CRISPR AND CAS GENES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL CRISPR AND CAS GENES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies
• 9.4 Company Regional Footprint
• 9.5 Company Industry Footprint
• 9.6 ACE Matrix

10 COMPANY PROFILES

• 10.1 OriGene Technologies, Inc
  • 10.1.1 Company Overview
  • 10.1.2 Company Insights
  • 10.1.3 Business Breakdown
  • 10.1.4 Product Benchmarking
  • 10.1.5 Key Developments
  • 10.1.6 Winning Imperatives
  • 10.1.7 Current Focus & Strategies
  • 10.1.8 Threat from Competition
  • 10.1.9 SWOT Analysis
• 10.2 Thermo Fisher Scientific
  • 10.2.1 Company Overview
  • 10.2.2 Company Insights
  • 10.2.3 Business Breakdown
  • 10.2.4 Product Benchmarking
  • 10.2.5 Key Developments
  • 10.2.6 Winning Imperatives
  • 10.2.7 Current Focus & Strategies
  • 10.2.8 Threat from Competition
  • 10.2.9 SWOT Analysis
• 10.3 Takara Bio Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Insights
  • 10.3.3 Business Breakdown
  • 10.3.4 Product Benchmarking
  • 10.3.5 Key Developments
  • 10.3.6 Winning Imperatives
  • 10.3.7 Current Focus & Strategies
  • 10.3.8 Threat from Competition
  • 10.3.9 SWOT Analysis
• 10.4 Horizon Discovery Ltd.
  • 10.4.1 Company Overview
  • 10.4.2 Company Insights
  • 10.4.3 Business Breakdown
  • 10.4.4 Product Benchmarking
  • 10.4.5 Key Developments
  • 10.4.6 Winning Imperatives
  • 10.4.7 Current Focus & Strategies
  • 10.4.8 Threat from Competition
  • 10.4.9 SWOT Analysis
• 10.5 Addgene
  • 10.5.1 Company Overview
  • 10.5.2 Company Insights
  • 10.5.3 Business Breakdown
  • 10.5.4 Product Benchmarking
  • 10.5.5 Key Developments
  • 10.5.6 Winning Imperatives
  • 10.5.7 Current Focus & Strategies
  • 10.5.8 Threat from Competition
  • 10.5.9 SWOT Analysis
• 10.6 Merck KGaA
  • 10.6.1 Company Overview
  • 10.6.2 Company Insights
  • 10.6.3 Business Breakdown
  • 10.6.4 Product Benchmarking
  • 10.6.5 Key Developments
  • 10.6.6 Winning Imperatives
  • 10.6.7 Current Focus & Strategies
  • 10.6.8 Threat from Competition
  • 10.6.9 SWOT Analysis
• 10.7 Caribou Biosciences, Inc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Insights
  • 10.7.3 Business Breakdown
  • 10.7.4 Product Benchmarking
  • 10.7.5 Key Developments
  • 10.7.6 Winning Imperatives
  • 10.7.7 Current Focus & Strategies
  • 10.7.8 Threat from Competition
  • 10.7.9 SWOT Analysis
• 10.8 CRISPR THERAPEUTICS
  • 10.8.1 Company Overview
  • 10.8.2 Company Insights
  • 10.8.3 Business Breakdown
  • 10.8.4 Product Benchmarking
  • 10.8.5 Key Developments
  • 10.8.6 Winning Imperatives
  • 10.8.7 Current Focus & Strategies
  • 10.8.8 Threat from Competition
  • 10.8.9 SWOT Analysis
• 10.10 Editas Medicine
  • 10.9.1 Company Overview
  • 10.9.2 Company Insights
  • 10.9.3 Business Breakdown
  • 10.9.4 Product Benchmarking
  • 10.9.5 Key Developments
  • 10.9.6 Winning Imperatives
  • 10.9.7 Current Focus & Strategies
  • 10.9.8 Threat from Competition
  • 10.9.9 SWOT Analysis
• 10.10 Mirus Bio LLC.
  • 10.10.1 Company Overview
  • 10.10.2 Company Insights
  • 10.10.3 Business Breakdown
  • 10.10.4 Product Benchmarking
  • 10.10.5 Key Developments
  • 10.10.6 Winning Imperatives
  • 10.10.7 Current Focus & Strategies
  • 10.10.8 Threat from Competition
  • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 APPENDIX

• 12.1 Related Research